40+ results for "iot"
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) Funding Update
HENDERSON, Nev., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) is continuing its ongoing negotiation with investors from Thailand, Japan, Switzerland, Luxembourg, USA, Bulgaria, and the UAE for financing of up to 50 million US dollars. The Company has seen great interest, with most investors reaching out directly to NIKA. “We are striving to select the most suitable investor and partner for NIKA, for which reason the discussions surrounding the technical details of
Standard Process Launches GI Soothing Supplement for Dogs and Cats
New probiotic, postbiotic, and botanical formula provides comprehensive gastrointestinal support during periods of digestive upset or distress A Media Snippet accompanying this announcement is available by clicking on this link. PALMYRA, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Standard Process® , a leader in whole food-based nutritional solutions, today announced GI Soothing , the newest addition to its Standard Process Veterinary line of human-quality supplements. Now available for preorder, GI
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September: Wells Fargo 2026 Healthcare Conference : Wednesday, September
Nu-Tek BioSciences to Attend BPI East 2026 in Boston, Connecting Animal-Free Culture Media Nutrients with Pharma Customer Growth Strategies
Tour Nu-Tek's state-of-the-art, 100% animal-free manufacturing facilty. Soy Peptone Soy peptones are one of the many animal-free products in Nu-Tek's raw materials portfolio. Nu-Tek will meet with pharmaceutical leadership during BioProcess International East Sept. 22-25 in Boston to discuss 100% animal-origin-free peptones and protein hydrolysates, with a focus on product quality and supply security. MINNETONKA, Minn., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nu-Tek BioSciences, the market leader in 1
Annovis to Host Corporate Update Webinar on September 2, 2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upc
Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
Presentation addressed potential applications in prolonged field care and military wound management settings WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference rev
Ocugen to Participate in Upcoming September Investor and Industry Conferences
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026. Citi 2026 Biopharma Back to School Conference Location: JW Marriott Essex House, New York City, NY Date: Wednesday, September 9, 2026 Time: 3:40–4:15 p.m. ET Forma
Longeveron Announces 1-for-10 Reverse Stock Split
Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectivel
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026. Mr. Edwards brings more than 25 years of commercial leadership experience across im
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Gamgertamig is being developed by Lakefro
Lakefront Receives Transparency Notification from Bank of America
Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation 1 , Lakefront received a transparency notification from Bank of America Corporation on August 19, 2026. The notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 10% of Lakefront’ voting rights on August 18, 2026,
Zealand Pharma – Notification of holding of treasury shares
Company announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports its notification pursuant to Section 31 of the Danish Capital Markets Act relating to its holding of treasury shares. As of 21 August 2026, the Company holds nominally 3,597,842 treasury shar
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 34 (August 17 - August 21, 2026). The Program is carried out in accordance with Article 5 of Regu
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication – SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S foll
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21 st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA. Wells Fargo 21 st Annual Healthcare Conference Format : One-on-one Meetings Date : Thursday, Sep
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first patient has been dosed
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” will be presented by Dr. Pinar Uysal today, Monday, August 24, 2026, from 4:30–6:30 p.m.
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, and Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a company redefining the discovery and de
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance’s common stock to twenty new, non
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to H
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapy Pivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and alignment with FDA that a single successful pivotal trial could potential
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised its option to cancel the proposed licensing of APA-01 to Restora Neurosciences, and will evaluate in-house and co-development pathways Canaccord Genuity LLC has been engaged as exclusive financial advisor and placement agent TORONTO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“
Adaptin Bio Announces Opening of Enrollment in a Phase 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101
APTN-101’s unique mechanism of action is designed to overcome the limitations for effective treatment of malignant brain tumors by enhancing the transport of therapies across the blood-brain barrier and selectively targeting EGFRvIII + glioma cells Phase 1 study being conducted in collaboration with Duke University CHARLOTTE, N.C., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio , Inc. (OTCQB: APTN) (“Adaptin” or the “Company”), a biotechnology company focused on developing precision cancer therap
Chandigarh University Students' 'Green Heart' Wins NASSCOM's Best Startup Award, Bags ₹5 Lakh Grant to Transform Farming with AI, Satellites & IoT
From Campus Innovation to AgriTech Breakthrough: Chandigarh University Students Green Heart Wins NASSCOM s Best Startup Award CHANDIGARH, India , Aug. 11, 2026 -- A Chandigarh University student startup has secured the Best Startup Award, along with a Rs 5,00,000 grant for its Al-driven smart agriculture technology platform GreenHeart at Neovation 2026 (ThingQbator), a prestigious innovation and startup incubation initiative organized by NASSCOM, the apex body representing India s 250-billion technology sector.
12 Value-Added Courses at Chandigarh University Uttar Pradesh, AI, Business Analytics & More to Boost Student Skills
Artificial Intelligence, Business Analytics, Design Thinking and IoT to enhance employment opportunities for students LUCKNOW, India , Aug. 8, 2026 -- Chandigarh University Uttar Pradesh has integrated 12 value-added courses into its academic curriculum. These credit-based courses aim to equip students with additional skills alongside their degree, addressing demands in both the current job market and higher education. Artificial Intelligence, Business Analytics, Design Thinking and IoT will now become part of regular curriculum for students.
SABESP Partners with Vivo and IDEMIA Secure Transactions, to Power the World's Largest IoT Initiative for a Secure and More Sustainable Water Management in Brazil
SABESP, the water and sanitation company of the State of S o Paulo, Brazil, announces the deployment of the world s largest Internet of Things (IoT) connectivity project for smart water management. The initiative is being implemented in partnership with Telefonica/Vivo, a key player in Brazil s technological transformation and one of the largest mobile operators in the continent, and IDEMIA Secure Transactions (IST), a global leader in payment and connectivity solutions, marking a significant milestone in the country s digital and environmental transformation.
Manipal Hospital, Bengaluru Installs India's First Elekta Evo, Advancing AI-Enabled Adaptive Radiotherapy in India
BENGALURU, India , July 31, 2026 -- In a significant advancement for cancer care in India, Manipal Hospital, Yelahanka, Bengaluru has become the first healthcare institution in the country to install Elekta Evo, the company s AI-enhanced adaptive CT-Linac platform. The installation enables clinicians to deliver Online Adaptive Radiotherapy (ART), supporting more personalised and precision-led radiation therapy for patients.
Elevated Materials Strengthens Commercial Leadership with Appointment of Jay Wang as Chief Revenue Officer
Jay Wang brings global commercial leadership across semiconductors, LEDs, and advanced battery markets as Elevated Materials expands customer adoption of its ultra-thin lithium films. SANTA CLARA, Calif. , July 30, 2026 -- Elevated Materials, a leading manufacturer of ultra-thin lithium films for next-generation batteries, today announced the appointment of Jay Wang as Chief Revenue Officer. Jay brings more than two decades of global sales, business development, and general management experience across battery, semiconductors, LEDs, and advanced technology markets. He has led commercial organizations across Asia and the United States, building high-performing teams, expanding customer relationships, and driving revenue growth across automotive, consumer electronics, AI, networking, IoT, and industrial markets.
Chandigarh University's Biotechnology & Pharmacy Students Secure 178 Placements with Leading Pharmaceutical and Biotechnology Companies
Leading national & global companies like Sun Pharma, GSK, Medtronic India, Serum Institute of India recruit Chandigarh University students CHANDIGARH, India , July 30, 2026 -- The rapid growth of Biotechnology, Pharmaceutical Sciences and allied healthcare fields has triggered a high demand for professionals equipped with specialized knowledge, practical skills and industry exposure. To meet this growing demand, Chandigarh University has integrated experiential learning model into its Biotechnology and Pharmaceutical Sciences programmes with 178 students securing placements and 261 students gaining industry internships in leading pharmaceutical companies, reputed healthcare institutions (hospitals) and life sciences organisations over the past three years.
Seaweed extract shown to relieve prostate symptoms
In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH). HOBART, Australia , July 27, 2026 -- A randomised, double-blind, placebo-controlled clinical trial evaluated the effects of fucoidan, a naturally occurring compound found in brown seaweed, on men with BPH (prostate enlargement). BPH is a common health issue for men across the globe. Worldwide estimates place prevalence at 50-60% of men in their 60s, increasing to 90% of men in their 80s. While it is typically not life-threatening, urinary symptoms including difficulty passing urine, a weak stream and an increase in the frequency of urination often result in a significant reduction in quality-of-life.
Chandigarh University's 272 Allied Health Sciences Students Secure Jobs in Prestigious Govt & Private Hospitals in Past 3 Years
University Boosts Employability with Internships for 393 Allied Health Sciences Students at Top Health Institutions CHANDIGARH, India , July 25, 2026 -- Chandigarh: Chandigarh University (CU) students of Allied Health Sciences -- Optometry, Forensic Science, Medical Laboratory Science, Nutrition and Dietetics and Physiotherapy - have secured over 272 jobs in leading corporate organisations and prestigious government and private healthcare institutions including AIIMS Rishikesh, PGIMER Chandigarh, Fortis Hospital, Max Super Specialty Hospital and government-run Forensic Science Laboratories during the past three years, reflecting CU s world-class education, industry-oriented curriculum, hands-on clinical training and robust placement ecosystem that prepares students for successful careers in healthcare.
Apollo Hospitals Brings Next-Generation Lysin Science to India's Fight Against AMR - Collaborates with Precisio Biotix
HYDERABAD, India , July 21, 2026 -- Apollo Hospitals today announced a strategic collaboration with Precisio Biotix to accelerate the development and clinical adoption of lysin-based antimicrobials in India - marking a significant step forward in combating antimicrobial resistance (AMR). This partnership will focus on translational research, clinical validation, and potential deployment pathways for lysin-based therapies across Apollo s network, with a focus on infectious diseases where existing treatment options are limited.
CancerFax Builds Trusted India-China Pathway for Advanced Cancer Treatment Access
CancerFax is strengthening its end-to-end patient navigation support for Indian and international patients exploring advanced oncology treatment options at leading hospitals in China, with an emphasis on hospital-based medical evaluation and responsible access. NEW DELHI , July 13, 2026 -- As China continues to gain attention for advanced oncology treatments including cancer gene therapy, CAR-T cell therapy, immunotherapy, advanced radiotherapy, and clinical trial programs, CancerFax has strengthened its India China patient navigation pathway to help eligible patients and families explore these options through responsible medical evaluation and hospital coordination.
Basecamp Research brings EDEN's antibiotic and vaccine design models to Claude Science
Scientists can now design potent antibiotics and rapidly prioritise vaccine targets through Claude Science, thanks to integration with Basecamp Research s EDEN models. LONDON and CAMBRIDGE, Mass. , June 30, 2026 -- Basecamp Research today announced that its antibiotic design and vaccine target prediction EDEN models are now available through Claude , including Claude Science, Anthropic s AI workbench for life sciences research. This allows researchers to generate and prioritise therapeutic candidates through a conversational interface in a matter of minutes.
Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI
More than 450 executives from 100+ leading life sciences organizations gathered in Princeton, NJ to move agentic AI past the proof-of-concept stage Founder and CEO Jaswinder Jassi Chadha challenged the industry with a counterintuitive mandate: before you build more agents, fix the foundation first The Ignite Leadership Awards honored transformation leaders from Bristol Myers Squibb, GSK, and Biogen; the Axtria Bedrock Honor recognized a 15-year partnership with Quest Diagnostics BERKELEY HEIGHTS, N.J. , June 25, 2026 -- Axtria Inc ., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme Industrializing Intelligence: The Agentic Enterprise. More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed.
Dahua Technology Showcases "Visible AI in New Energy" at Intersolar Europe 2026
MUNICH , June 25, 2026 -- Dahua Technology, a world-leading video-centric AIoT solution and service provider, showcased its latest innovations for the renewable energy industry at Intersolar Europe 2026. Under the theme Visible AI in New Energy, Dahua demonstrated how AIoT technologies can help energy operators enhance efficiency, reliability, and security across the entire energy value chain, from power generation and transmission to consumption. At this year s exhibition, Dahua presented a comprehensive portfolio of solutions covering five key application areas: Intelligent Security, Equipment Inspection, HSE-PPE Management, EV Charging, and Smart Control Centre. Together, these solutions address the growing need for smarter operations, safer workplaces, and more efficient asset management across renewable energy infrastructure.
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)
YOKOHAMA, Japan , June 24, 2026 -- REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal , for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal to suppress the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6). Under the established framework, Stemchymal will be manufactured by Taiwan-based Steminent Biotherapeutics Inc., with REPROCELL overseeing all sales and distribution activities within Japan.
Geri Care launches Coimbatore's first geriatrician-led Skilled Nursing Facility & Long-term Care Hospital for Senior Citizens
100-bed facility designed exclusively for the healthcare needs of older adults Brings post-hospitalization and post-surgery care, rehabilitation, assisted living, dementia care and palliative care under one continuum COIMBATORE, India , June 17, 2026 -- Geri Care, India s pioneer in integrated eldercare , today launched Coimbatore s first geriatrician-led Skilled Nursing Facility (SNF) and Long-term Care Hospital dedicated exclusively to senior citizens. Located centrally at Lakshmi Mills Junction, opposite Lulu Mall, the 100-bed facility has been purpose-built to address the evolving healthcare needs of older adults. The centre will also operate as a Geriatric Multispecialty Outpatient Clinic for Senior Citizens, equipped with ECG, Echo, Ultrasound, Pharmacy, Labs, Vaccinations, Physiotherapy and Rehabilitation for the community.